Literature DB >> 25057863

Image guidance in malignant gliomas: a focused strategy.

Evangelia Katsoulakis1, Kathryn Beal, Yoshiya Yamada.   

Abstract

The standard of care for malignant gliomas is maximal surgical cytoreduction followed by concurrent chemoradiation and adjuvant chemotherapy with temozolomide. Chemotherapy adds a modest improvement in overall survival. Unfortunately, tumor recurrence is the rule and typically occurs at the initial site of disease. Salvage reirradiation may be a useful approach in selected patients with recurrent glioblastoma. Image-guided technology coupled with highly conformal treatment planning techniques have allowed the safe delivery of high-dose radiotherapy in the setting of tumor recurrence. Defining the optimal combination of hypofractionated stereotactic radiotherapy with chemotherapy is under investigation. In this perspective, we examine the role of image guidance in malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 25057863      PMCID: PMC6176790          DOI: 10.2217/cns.12.21

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  35 in total

1.  Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy.

Authors:  Ellen S Mandl; C M F Dirven; D R Buis; T J Postma; W P Vandertop
Journal:  Surg Neurol       Date:  2008-02-08

Review 2.  Rationale for carbon ion therapy in high-grade glioma based on a review and a meta-analysis of neutron beam trials.

Authors:  D Maucort-Boulch; M-H Baron; P Pommier; D C Weber; J-E Mizoe; J Rochat; J-P Boissel; J Balosso; H Tsujii; E Amsallem
Journal:  Cancer Radiother       Date:  2009-12-08       Impact factor: 1.018

3.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

Authors:  René-Olivier Mirimanoff; Thierry Gorlia; Warren Mason; Martin J Van den Bent; Rolf-Dieter Kortmann; Barbara Fisher; Michele Reni; Alba A Brandes; Jüergen Curschmann; Salvador Villa; Gregory Cairncross; Anouk Allgeier; Denis Lacombe; Roger Stupp
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

4.  Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme.

Authors:  S E Combs; S Gutwein; Ch Thilmann; P Huber; J Debus; D Schulz-Ertner
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

5.  Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma.

Authors:  N J Laperriere; P M Leung; S McKenzie; M Milosevic; S Wong; J Glen; M Pintilie; M Bernstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-15       Impact factor: 7.038

6.  Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Kunio Yokoyama; Toshihiko Kuroiwa; Hiroyuki Michiue; Yoshinori Sakurai; Hiroaki Kumada; Minoru Suzuki; Akira Maruhashi; Mitsunori Kirihata; Koji Ono
Journal:  J Neurooncol       Date:  2008-09-24       Impact factor: 4.130

7.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

8.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

9.  Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?

Authors:  Emmanouil Fokas; Ulrich Wacker; Markus W Gross; Martin Henzel; Elitsa Encheva; Rita Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

10.  PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.

Authors:  Dannis G van Vuurden; Esther Hulleman; Olga L M Meijer; Laurine E Wedekind; Marcel Kool; Hendrik Witt; Peter W Vandertop; Thomas Würdinger; David P Noske; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Oncotarget       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.